The uncertain standing of lithium therapy prompted this review of the literature. Lithium is a potentially toxic substance which rapidly obtained a lethal record after Cade (5) , in Australia in 1949, first reported its effectiveness in mania. This reputation for toxicity was earned in its use as a salt substitute during the low salt diet treatment of congestive cardiac failure, and it has had a retarding effect on the use of the drug. Interest has been steadily increasing in Europe, especially under the impetus of Schou, and has spread to North America where, however, it remains a restricted drug.
Evidence for effectiveness can be examined in three aspects: in the treat ment of the manic phase, the depressive phase and in prophylaxis or so-called mood normalizing.
Manic Phase
Up until 1959, eighteen reports (15) of the uncontrolled use of lithium gave an aggregated positive response of 304 out of 370, that is approximately 80 per cent improvement. A comparison with the use of electrotherapy in 466 patients also gave approximately 80 per cent im provement. Here, however, it was noted that improvement was limited to two or three weeks' duration, while that from lithium, when it occurred, was maintain ed for considerably longer.
On the face of it then we have a treat ment which is more effective than elec trotherapy. Direct comparison with the use of phenothiazine drugs has not been made in these studies. However, it was stated, or could be inferred, that manic illnesses which had not responded to phenothiazines were being selected for lithium trial.
This order of response of even 80 per cent in an uncontrolled trial is only sug gestive of effectiveness and it clearly in dicates but one conclusion, that lithium is not a complete answer to all cases of mania.
The unpredictability of response to lithium -dramatic in some cases and in others none at all, is a constantly re curring finding by clinical investigators. It is noteworthy and adds force to the reported effect of lithium in these trials that many investigators state that the im provement, if it takes place, can be ex pected within the first or second week.
Turning to the blind trials there are only two full clinical trials to be con sidered: Schou's (14) in 1954 and Maggs (11) in 1963.
On close inspection Schou's trial is open to a great deal of criticism; parts of the trial were blind and parts were not, and in reporting his results he fails to differentiate between the two. No quantification of the level of affect is made and the mathematical handling of results is inadequate. He classifies the 32 lithium responders out of his total of 38 subjects into two categories, definite responders and possible responders, accord ing to whether a differential effect of lithium and placebo could be observed. In his graphed results it is difficult to identify the effect of lithium versus placebo as the two are alternated at twoweekly intervals. In any event he found that 14 (that is approximately one third) had definitely responded and 18 possibly responded out of the 38 subjects. Patients were changed from nothing or placebo to lithium on 64 occasions; 2 became more manic, 17 were unchanged and 45 became less manic at the end of the twoweek period. Twenty-three patients were changed from lithium to nothing or placebo, 14 became more manic, 9 were unchanged and none became less manic. These are statistically highly significant findings and go far beyond chance ex pectation, but they are not the result of a blindly controlled trial.
Magg's trial, within certain limits im posed by the nature of clinical research into this type of problem, measured up very well to basic scientific requirements. Twenty-eight patients were commenced on a double-blind trial, nine did not com plete the trial and the results are based on eighteen patients, one being omitted to even up the groups. The patients were allocated to one of two groups, either 1) lithium for two weeks followed by a rest period for two weeks and sub sequently a placebo for two weeks, or 2) the reverse order. Measurement on a reliable rating scale demonstrated a statistically significant improvement while on lithium and a deterioration while on the placebo.
It is worth referring to the work of Bunney (4) who focused on two pa tients who were selected as known lithium responders. They were given lithium and placebo in a double-blind study. A behaviour rating scale and a psychiatric rating scale were used to assess the level of mania. There was a definite increase in mania reflected in daily ratings during the placebo period within 24 hours of withdrawal of lithium. It is interesting to note that response to lithium tended to occur in a period longer than 24 hours and usually in a period of at least several days.
These findings are quite striking and indicate how effective lithium can be in some cases of mania. However, neither of these trials really gives us information on the proportion of cases which can be expected to respond, although Schou's work suggests that this fraction is at least one third.
Depressive Phase
In the depressive phase of manic de pressive psychosis, and dealing first with open trials Cade (5) , the original investi gator, reported lithium as generally in effective, and many investigators with open trials have been similarly unim pressed. One investigator (13) thought it worsened some patients. An Italian investigation noted improvement in 10 out of 24 patients (1) . Only a chronic optimist would feel much confidence in embarking upon regular usage in depres sive attacks on this basis; diagnostic criteria were usually not stated and, as well as being uncontrolled, no objective measure of change in depressive levels was made.
Fieve (6) in a recent paper attempted to put matters right with a well-conduct ed study of 29 patients suffering from manic depressive psychosis in the de pressive phases. He stated his criteria for a diagnosis; all had at least one previous affective illness. The patients were as signed to placebo for four weeks and then given a further three weeks on imipramine, lithium or placebo in a ran domized double-blind manner. Depres sion was measured by scores on rating scales. These measures remained steady while on placebo, decreased by 32 per cent on lithium and 58 per cent on imi pramine. The antidepressive effect of lithium over this three-week period was rated as mild compared with imipramine and it certainly warrants our attention, but comparisons have not been made with phenothiazine and non-phenothiazine tranquillizers.
Suggestions have already been made that a better result can be obtained by combining a tricyclic antidepressive drug with lithium (16) . This may well be so but the impressionistic results available at present allow no firm conclusions.
Another unsubstantiated indication for the use of lithium is in combination with antidepressive drugs or electro therapy when treating the depressive phase of manic depressive psychosis, in order to diminish the possibility of re bound into mania.
Prophylaxis
Reports (2, 9) have appeared which maintain that lithium on a long-term basis has reduced the frequency of both manic and depressive relapses in manic depressive psychosis. Baastrup and Schou (3) in a recent paper produced evidence which has been influential in this view. Even superficial reading reveals consider able possible bias in this trial which was entirely open. Detailed examination whittles away the impressive perform ance they claim to a level which be comes only suggestive of effectiveness. Naturally without a control group no firm conclusion is possible and, in fact, not a single substantiative comparative paper exists in the literature today.
Preliminary reports of two further studies have recently become available: Hullin (10) reporting on a four-year study in 40 patients found a significant effect in many patients but with appar ently little, if any, in others. Melia (12) has given us an interim report of a study of 9 patients in a control and 9 in a treat ment group followed over two years. Remission was better maintained in the treatment group but not to a statistically significant level.
If the action of lithium in manic de pressive psychosis is to suppress mania alone, or both mania and also depression to some extent, one would expect a socalled prophylactic action to be as evi dent as that produced by treating indivi duals as soon as fresh relapses occurred. The implication of Schou and other workers when they use the term 'mood normalizer' is that there is an indirect prophylactic action over and above this. The indication for this is weak.
Practical Implications
The over-all conclusions which can be drawn are that lithium is effective in a significant proportion of attacks of mania, and a trial of the drug is appro priate in all cases which are not improved by phenothiazine therapy. Response, if it occurs, is often evident within 48 hours (4) and can be expected within two weeks (10) .
It cannot be said that lithium has a prominent place in the treatment of a depressive phase of manic depressive psychosis, and certainly not in depres sion generally. Reports that effective results can be obtained by combining antidepressive drugs with lithium (7) have been based on clinical impressions of individual cases, and form an inade quate basis for routine practice. Careful clinical observation of the patient during a therapeutic trial of probably three or four weeks is indicated, and the subse quent withdrawal and readministration of the drug may be necessary to establish a temporal association between drug and improvement.
Lithium in its psychiatric usage is less dangerous than originally thought. Pro dromal toxic effects, such as fatigue, headache, tremulousness and drowsiness (16) , give sufficient warning and are more sensitive and immediate (11) than routine serum lithium analysis. But it is important to realize that the safety factor is of a low order, comparable with barbiturates, and the drug offers a poten tial means of suicide for non-responding patients who have lapsed into depression.
The fact that management of lithium dosage is clinical should not lead to the conclusion that lithium serum analysis need not be available. Renal clearance of lithium, the only means of elimination of the element, declines with age and in those of 50 and over it cannot be safely assumed that renal function is normal on the basis of the customary screening history, urinalysis and blood urea-nitro gen. Whilst treatment is being establish ed serum lithium estimation is clearly indicated with older patients and, in our present state of knowledge, is probably advisable at all ages.
The question of duration of therapy in apparently successful cases is un answered. The effects of long-term ad ministration may not be fully revealed; caution should continue to prevail, es pecially in women of child-bearing years.
Trial withdrawal can be periodically introduced during maintenance therapy and if pursued cautiously whilst the pa tient remains under regular surveillance, relapse can be detected early and lithium reintroduced without detriment to the patient. Summary
The significant literature on the use of lithium in manic depressive psychosis is reviewed. Lithium is highly effective in a proportion of attacks of mania. Its place in the depressive phase and in pro phylaxis is uncertain. Comments are made on its use in these three areas in the light of its established toxicity.
